nonalcoholic fatty liver disease nafld is the most common liver disease in the western world and its incidence is increasing rapidlynafld is a spectrum ranging from simple steatosis which is relatively benign hepatically to nonalcoholic steatohepatitis nash which can progress to cirrhosisobesity insulin resistance type 2 diabetes mellitus and dyslipidemia are the most important risk factors for naflddue to heavy enrichment with metabolic risk factors individuals with nafld are at significantly higher risk for cardiovascular diseaseindividuals with nafld have higher incidence of type 2 diabetesthe diagnosis of nafld requires imaging evidence of hepatic steatosis in the absence of competing etiologies including significant alcohol consumptionliver biopsy remains the gold standard for diagnosing nash and for determining prognosisweight loss remains a cornerstone of treatmentweight loss of 5 is believed to improve steatosis whereas 10 weight loss is necessary to improve steatohepatitisa number of pharmacologic therapies have been investigated to treat nash and agents such as vitamin e and thiazolidinediones have shown promise in select patient subgroups